{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:10:14Z","timestamp":1792044614186,"version":"4.4.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmogastro.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Gastrointestinal Oncology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.esmogo.2024.100128","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T21:57:02Z","timestamp":1736200622000},"page":"100128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Managing zolbetuximab-induced nausea and vomiting: a proposal for a pragmatic approach in clinical practice"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4559-5699","authenticated-orcid":false,"given":"K.","family":"Shimozaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7618-5775","authenticated-orcid":false,"given":"A.","family":"Ooki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Yamahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Tamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Udagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Fukuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Osumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Wakatsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Shinozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9742","key":"10.1016\/j.esmogo.2024.100128_bib1","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"10294","key":"10.1016\/j.esmogo.2024.100128_bib2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.esmogo.2024.100128_bib3","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.esmogo.2024.100128_bib4","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1007\/s10120-024-01518-1","article-title":"Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma","volume":"27","author":"Shitara","year":"2024","journal-title":"Gastric Cancer"},{"issue":"8","key":"10.1016\/j.esmogo.2024.100128_bib5","doi-asserted-by":"crossref","DOI":"10.1200\/PO.23.00543","article-title":"Retrospective study of claudin 18 isoform 2 prevalence and prognostic association in gastric and gastroesophageal junction adenocarcinoma","volume":"2024","author":"Waters","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"23","key":"10.1016\/j.esmogo.2024.100128_bib6","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","article-title":"Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development","volume":"14","author":"Sahin","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.esmogo.2024.100128_bib7","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1093\/annonc\/mdz199","article-title":"A\u00a0multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study","volume":"30","author":"T\u00fcreci","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmogo.2024.100128_bib8","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1523096","article-title":"Characterization of zolbetuximab in pancreatic cancer models","volume":"8","author":"T\u00fcreci","year":"2019","journal-title":"OncoImmunology"},{"issue":"10389","key":"10.1016\/j.esmogo.2024.100128_bib9","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.esmogo.2024.100128_bib10","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.esmogo.2024.100128_bib11","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1056\/NEJMc2409512","article-title":"Zolbetuximab in gastric or gastroesophageal junction adenocarcinoma","volume":"391","author":"Shitara","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.esmogo.2024.100128_bib12","doi-asserted-by":"crossref","first-page":"7380","DOI":"10.1128\/MCB.21.21.7380-7390.2001","article-title":"Claudin-18, a novel downstream target gene for the T\/EBP\/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing","volume":"21","author":"Niimi","year":"2001","journal-title":"Mol Cell Biol"},{"issue":"2","key":"10.1016\/j.esmogo.2024.100128_bib13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.gene.2011.04.007","article-title":"Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals","volume":"481","author":"T\u00fcreci","year":"2011","journal-title":"Gene"},{"issue":"3","key":"10.1016\/j.esmogo.2024.100128_bib14","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jphs.2024.08.005","article-title":"Effect of antiemetics on zolbetuximab-induced gastric injury and emesis in ferrets","volume":"156","author":"Kinugasa","year":"2024","journal-title":"J\u00a0Pharmacol Sci"},{"issue":"3","key":"10.1016\/j.esmogo.2024.100128_bib15","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s10120-020-01153-6","article-title":"Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma","volume":"24","author":"Lordick","year":"2021","journal-title":"Gastric Cancer"},{"issue":"4","key":"10.1016\/j.esmogo.2024.100128_bib16","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.clinthera.2016.03.011","article-title":"Methods for implementing and reporting patient-reported outcome (PRO) measures of symptomatic adverse events in cancer clinical trials","volume":"38","author":"Basch","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.esmogo.2024.100128_bib17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejca.2018.11.013","article-title":"Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: exploratory analysis of RAINBOW and REGARD phase III trials","volume":"107","author":"Chau","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmogo.2024.100128_bib18","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S0167-8140(24)04217-8","article-title":"509 A virtual audit system for intensity-modulated radiation therapy credentialing in Japan clinical oncology group clinical trials","volume":"197","author":"Nakamura","year":"2024","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.esmogo.2024.100128_bib19","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1200\/JCO.21.01315","article-title":"Randomized, double-blind, phase III study of fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting: console","volume":"40","author":"Hata","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmogo.2024.100128_bib20","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/cncr.34088","article-title":"A\u00a0phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE-BC","volume":"128","author":"Matsuura","year":"2022","journal-title":"Cancer"},{"issue":"suppl 3","key":"10.1016\/j.esmogo.2024.100128_bib22","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1200\/JCO.2024.42.3_suppl.372","volume":"42","author":"Shitara","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.esmogo.2024.100128_bib23","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.22.01997","article-title":"Randomized double-blind placebo-controlled study of olanzapine for chemotherapy-related anorexia in patients with locally advanced or metastatic gastric, hepatopancreaticobiliary, and lung cancer","volume":"41","author":"Sandhya","year":"2023","journal-title":"J\u00a0Clin Oncol"}],"container-title":["ESMO Gastrointestinal Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S294981982400089X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S294981982400089X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T01:21:26Z","timestamp":1745025686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S294981982400089X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":22,"alternative-id":["S294981982400089X"],"URL":"https:\/\/doi.org\/10.1016\/j.esmogo.2024.100128","relation":{},"ISSN":["2949-8198"],"issn-type":[{"value":"2949-8198","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing zolbetuximab-induced nausea and vomiting: a proposal for a pragmatic approach in clinical practice","name":"articletitle","label":"Article Title"},{"value":"ESMO Gastrointestinal Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmogo.2024.100128","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100128"}}